Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25222902 | 0.84 | ALDH1A1 (0.35) | ALDH1A1TSHRTP53 | |
| SCHEMBL28169036 | 0.78 | TSHR (0.44) | ALDH1A1TSHRTP53 | |
| SCHEMBL3204789 | 0.78 | ALDH1A1 (0.32) | ALDH1A1TSHRTP53 | |
| SCHEMBL11730790 | 0.78 | TSHR (0.44) | ALDH1A1TSHRTP53 | |
| Tribromoacetic Acid SCHEMBL210187 | 0.76 | — | — | |
| Tribromoacetic Acid SCHEMBL1331874 | 0.76 | — | — | |
| SCHEMBL5610861 | 0.75 | ALDH1A1 (0.30) | ALDH1A1TSHRTP53 | |
| SCHEMBL25220521 | 0.75 | ALDH1A1 (0.30) | ALDH1A1TSHRTP53 | |
| SCHEMBL5610830 | 0.75 | ALDH1A1 (0.44) | ALDH1A1TSHRTP53CYP1A2 | |
| SCHEMBL5610999 | 0.75 | THRB (0.43) | ALDH1A1TSHRTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445533-B2 | Andrographolide derivatives to treat viral infections | CORNELL RESEARCH FOUNDATION, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-1817024-A2 | ANDROGRAPHOLIDE DERIVATIVES TO TREAT VIRAL INFECTIONS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060223785-A1 | Andrographolide derivatives to treat viral infections | CORNELL RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006101538-A2 | ANDROGRAPHOLIDE DERIVATIVES TO TREAT VIRAL INFECTIONS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223785-A1 | Andrographolide derivatives to treat viral infections | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 897/4885TSHR 4441/4885TP53 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.